Use of intranasal midazolam to treat acute seizures in paediatric community settings. 2004

M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
Department of Paediatrics and Child Health, Flinders Medical Centre, Adelaide, South Australia 5042, Australia. michael.harbord@flinders.edu.au

OBJECTIVE To evaluate the acceptability of intranasal midazolam (INM) in acute seizure management in the community. METHODS Parents and staff in residential and educational settings were trained in first aid and seizure management and the administration of INM. Feedback was obtained from those who had given INM over the 30-month period September 2000-March 2003. RESULTS Intranasal midazolam was administered to 22 children for a total of 54 seizures (range 1-6 seizures each). The dose was 0.2-0.3 mg/kg rounded down to 1 or 2 of the 5 mg in 1-mL plastic ampoules, with the anticonvulsant instilled into the child's nose directly from the plastic ampoule. Seizures were effectively stopped on 48 occasions, i.e. 89%, while no respiratory arrests occurred. Thirty carers had given INM to a convulsing child and 27 (90%) reported no difficulty in administering it. Fifteen people had also previously administered rectal diazepam and INM was considered easier to administer than rectal diazepam by 13 while a preference to use INM rather than rectal diazepam was indicated by 14. CONCLUSIONS This study has shown that INM is an acceptable treatment option as a first aid response for acute seizures. We believe that INM should be considered as the preferred alternative in the community setting, as it is easier to administer and is more dignified for the patient than rectal diazepam.

UI MeSH Term Description Entries
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003153 Community Health Services Diagnostic, therapeutic and preventive health services provided for individuals in the community. Community Health Care,Community Healthcare,Health Services, Community,Services, Community Health,Community Health Service,Health Care, Community,Health Service, Community,Healthcare, Community,Service, Community Health
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations

Related Publications

M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
January 2020, Epilepsy currents,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
May 2006, Pediatric neurology,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
January 2004, Revista de neurologia,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
August 1998, Lancet (London, England),
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
October 2012, CNS drugs,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
April 2013, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
September 2000, Brain & development,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
May 2001, Emergency medicine journal : EMJ,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
August 2008, Anaesthesia,
M G Harbord, and N E Kyrkou, and M R Kyrkou, and D Kay, and K P Coulthard
December 2007, Anaesthesia,
Copied contents to your clipboard!